Recent Finacing
Recent Raise
Intercept Pharmaceuticals is a clinical-stage biopharmaceutical company developing modified bile-acid small molecules targeting nuclear receptor FXR, GPCR TGR5 and other bile-acid receptors, including OCA for primary biliary cirrhosis.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors